A Phase 3 interventional study of pregabalin in Spinal Cord Diseases, Spinal Cord Injuries and Neuralgia, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 26 sites in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-01-28.
Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to assess the safety of the long-term use of pregabalin at doses up to 600 mg/day in patients with central neuropathic pain (post spinal cord injury pain, post stroke pain, and multiple sclerosis pain).
2,028 studies on the registry are indexed under Spinal Cord Injuries; 540 are open to participants now.
This study's enrollment of 104 is above the median of 24 across 1,635 interventional studies indexed under Spinal Cord Injuries.
Browse Spinal Cord Injuries studies →Pfizer's Upjohn has merged with Mylan to form Viatris Inc. is the lead sponsor of 434 studies on the registry; none are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.
First submitted before Pfizer's Upjohn has merged with Mylan to form Viatris Inc. became part of Viatris Inc..
Compared within Spinal Cord Injuries, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Spinal Cord Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Inclusion criteria for subjects to be shifted from Study A0081107
Inclusion criteria for subjects to be new participants in this study
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Flexible dosing in 4 weeks followed by 48 weeks maintenance and one week taper period
Drug: pregabalin
Pregabalin capsules taken twice a daily (150-600mg/day)
Number of Participants With Peripheral Edema
Number of participants who had peripheral edema in lower extremities. Edema was categorized as follows: trace, pitting 1 (lower leg), 2 (lower leg to knee), and 3 (above knee and /or presacral edema).
Time frame: Baseline, Weeks 4, 20, 36, 52, and 53
Number of Participants With Facial/Periorbital Edema
Number of participants who had facial or periorbital edema.
Time frame: Baseline, Weeks 4, 20, 36, 52, and 53
Number of Participants With Generalized or Abdominal Edema
Number of participants who had generalized or abdominal edema.
Time frame: Baseline, Weeks 4, 20, 36, 52, and 53
Number of Participants With Localized Pain Related to Deep Vein Thrombosis (DVT)
DVT was defined if a segment of the deep vein of the lower limb was not compressible or a previous compressive vein became non compressive or there was no flow in the underlying vessel. Symptoms of DVT included pain in the lower limb, localized tenderness, swelling, pitting edema, collateral superficial veins (non-varicose), and skin redness. The symptom was assessed as mild, moderate or severe.
Time frame: Baseline, Weeks 4, 20, 36, 52, and 53
Number of Participants With Localized Tenderness Related to Deep Vein Thrombosis (DVT)
DVT was defined if a segment of the deep vein of the lower limb was not compressible or a previous compressive vein became non compressive or there was no flow in the underlying vessel. Symptoms of DVT included pain in the lower limb, localized tenderness, swelling, pitting edema, collateral superficial veins (non-varicose), and skin redness. The symptom was assessed as mild, moderate or severe.
Time frame: Baseline, Weeks 4, 20, 36, 52, and 53
Number of Participants With Swelling Related to Deep Vein Thrombosis (DVT)
DVT was defined if a segment of the deep vein of the lower limb was not compressible or a previous compressive vein became non compressive or there was no flow in the underlying vessel. Symptoms of DVT included pain in the lower limb, localized tenderness, swelling, pitting edema, collateral superficial veins (non-varicose), and skin redness. The symptom was assessed as mild, moderate or severe.
Time frame: Baseline, Weeks 4, 20, 36, 52, and 53
Number of Participants With Pitting Edema Related to Deep Vein Thrombosis (DVT)
DVT was defined if a segment of the deep vein of the lower limb was not compressible or a previous compressive vein became non compressive or there was no flow in the underlying vessel. Symptoms of DVT included pain in the lower limb, localized tenderness, swelling, pitting edema, collateral superficial veins (non-varicose), and skin redness. The symptom was assessed as mild, moderate or severe.
Time frame: Baseline, Weeks 4, 20, 36, 52, and 53
Number of Participants With Collateral Superficial Veins (Non-varicose) Related to Deep Vein Thrombosis (DVT)
DVT was defined if a segment of the deep vein of the lower limb was not compressible or a previous compressive vein became non compressive or there was no flow in the underlying vessel. Symptoms of DVT included pain in the lower limb, localized tenderness, swelling, pitting edema, collateral superficial veins (non-varicose), and skin redness. The symptom was assessed as mild, moderate or severe.
Time frame: Baseline, Weeks 4, 20, 36, 52, and 53
Number of Participants With Skin Redness Related to Deep Vein Thrombosis (DVT)
DVT was defined if a segment of the deep vein of the lower limb was not compressible or a previous compressive vein became non compressive or there was no flow in the underlying vessel. Symptoms of DVT included pain in the lower limb, localized tenderness, swelling, pitting edema, collateral superficial veins (non-varicose), and skin redness. The symptom was assessed as mild, moderate or severe.
Time frame: Baseline, Weeks 4, 20, 36, 52, and 53
Number of Participants With Visual Field Deteriorated
Number of participants who had normal visual field at baseline and showed abnormal result after the study treatment, assessed by confrontational visual field test (neurological examination).
Time frame: 53 weeks
Number of Participants With Deterioration in Neurological Examination Findings
Worsening of the condition relative to baseline was reported as deteriorated. Assessment categories are as follows: normal or abnormal for Cranial Nerve Function, Mental State, and Coordination; normal, mild, moderate, or severe ataxia for Gait; none/absent, normal, or hyper-reflexic for Deep Tendon Reflexes; absent or present for Abnormal Reflexes; normal, mild, moderate, or severe weakness for Muscle Strength; slight, more marked, or considerable increase, or affected parts rigid in flexion or extension for Muscle Tone; absent or present for Sensory Function.
Time frame: 53 weeks
Number of Participants With Suicidal Ideation According to Sheehan Suicidality Tracking Scale (Sheehan-STS)
The Sheehan-STS is an 8-item prospective rating scale that tracks treatment-emergent suicidal ideation and behaviors. Participants who reported a score of ≥1 (5-point scale ranging from 0: not at all to 4: extremely) for Item 2, 3, 4 or 5 of the Sheehan-STS prognostic scale is considered to have suicidal ideation as the scores are mapped to Category 4 (suicide ideation) of the Columbia Classification Algorithm of Suicide Assessment.
Time frame: Baseline, Weeks 2, 4, 8, 12, 20, 28, 36, 44, and 52
Change From Baseline in Short-Form McGill Pain Questionnaire (SF-MPQ) at Each Time Point: Total Scores
The main component of the SF-MPQ consists of 15 descriptors (11 sensory; 4 affective) which are rated on an intensity scale as 0 = none, 1 = mild, 2 = moderate or 3 = severe. Range: 0 to 45 for total score. Change = observation mean minus baseline mean. Negative change indicated improvement.
Time frame: Baseline, Weeks 2, 4, 8, 12, 20, 28, 36, 44, and 52
Change From Baseline in Short-Form McGill Pain Questionnaire (SF-MPQ) at Each Time Point: Sensory Scores
The main component of the SF-MPQ consists of 15 descriptors (11 sensory; 4 affective) which are rated on an intensity scale as 0 = none, 1 = mild, 2 = moderate or 3 = severe. Range: 0 to 33 for sensory score. Change = observation mean minus baseline mean. Negative change indicated improvement.
Time frame: Baseline, Weeks 2, 4, 8, 12, 20, 28, 36, 44, and 52
Change From Baseline in Short-Form McGill Pain Questionnaire (SF-MPQ) at Each Time Point: Affective Scores
The main component of the SF-MPQ consists of 15 descriptors (11 sensory; 4 affective) which are rated on an intensity scale as 0 = none, 1 = mild, 2 = moderate or 3 = severe. Range: 0 to 12 for affective score. Change = observation mean minus baseline mean. Negative change indicated improvement.
Time frame: Baseline, Weeks 2, 4, 8, 12, 20, 28, 36, 44, and 52
Change From Baseline in the Modified Brief Pain Inventory (10 Item) (mBPI-10)Total Scores at Last Evaluation Score
The mBPI-10 is a self administered questionnaire that assesses pain interference with functional activities over the past week. These items are measured on an 11 point scale, ranging from "does not interfere" (0) to "completely interferes" (10). A composite score, the Pain Interference Index, will be calculated by averaging the 10 items that comprise the scale. Change = observation mean at Week 52 minus baseline mean.
Time frame: Baseline, Week 52
Japanese patients with central neuropathic pain after spinal cord injury who had completed the preceding A0081107 study (NCT00407745) were eligible for this study, and Japanese patients with pain after cerebral stroke or with multiple sclerosis pain were newly recruited.
| Milestone | Pregabalin |
|---|---|
| Started | 103 |
| Completed | 84 |
| Not completed | 19 |
| Withdrew: Adverse event | 16 |
| Withdrew: Withdrawal by subject | 2 |
| Withdrew: Lack of efficacy | 1 |
Number of participants who had peripheral edema in lower extremities. Edema was categorized as follows: trace, pitting 1 (lower leg), 2 (lower leg to knee), and 3 (above knee and /or presacral edema).
| Participants | Pregabalin |
|---|---|
| Trace at Baseline (n=103) | 5 |
| Pitting +1 at Baseline (n=103) | 9 |
| Pitting +2 at Baseline (n=103) | 2 |
| Pitting +3 at Baseline (n=103) | 0 |
| Trace at Week 4 (n=101) | 8 |
| Pitting +1 at Week 4 (n=101) | 8 |
| Pitting +2 at Week 4 (n=101) | 4 |
| Pitting +3 at Week 4 (n=101) | 1 |
| Trace at Week 20 (n=93) | 8 |
| Pitting +1 at Week 20 (n=93) | 3 |
| Pitting +2 at Week 20 (n=93) | 7 |
| Pitting +3 at Week 20 (n=93) | 0 |
| Trace at Week 36 (n=90) | 14 |
| Pitting +1 at Week 36 (n=90) | 7 |
| Pitting +2 at Week 36 (n=90) | 3 |
| Pitting +3 at Week 36 (n=90) | 0 |
| Trace at Week 52/early termination (n=100) | 10 |
| Pitting +1 at Week 52/early termination (n=100) | 7 |
| Pitting +2 at Week 52/early termination (n=100) | 2 |
| Pitting +3 at Week 52/early termination (n=100) | 0 |
| Trace at Week 53/early termination (n=78) | 9 |
| Pitting +1 at Week 53/early termination (n=78) | 5 |
| Pitting +2 at Week 53/early termination (n=78) | 0 |
| Pitting +3 at Week 53/early termination (n=78) | 0 |
Number of participants who had facial or periorbital edema.
| Participants | Pregabalin |
|---|---|
| Baseline (n=103) | 0 |
| Week 4 (n=101) | 0 |
| Week 20 (n=93) | 0 |
| Week 36 (n=90) | 0 |
| Week 52/early termination (n=100) | 1 |
| Week 53/early termination (n=78) | 0 |
Number of participants who had generalized or abdominal edema.
| Participants | Pregabalin |
|---|---|
| Baseline (n=103) | 0 |
| Week 4 (n=101) | 0 |
| Week 20 (n=93) | 0 |
| Week 36 (n=90) | 0 |
| Week 52/early termination (n=100) | 1 |
| Week 53/early termination (n=78) | 0 |
DVT was defined if a segment of the deep vein of the lower limb was not compressible or a previous compressive vein became non compressive or there was no flow in the underlying vessel. Symptoms of DVT included pain in the lower limb, localized tenderness, swelling, pitting edema, collateral superficial veins (non-varicose), and skin redness. The symptom was assessed as mild, moderate or severe.
| Participants | Pregabalin |
|---|---|
| Mild at Baseline (n=103) | 2 |
| Moderate at Baseline (n=103) | 3 |
| Severe at Baseline (n=103) | 1 |
| Mild at Week 4 (n=101) | 5 |
| Moderate at Week 4 (n=101) | 1 |
| Severe at Week 4 (n=101) | 0 |
| Mild at Week 20 (n=93) | 3 |
| Moderate at Week 20 (n=93) | 0 |
| Severe at Week 20 (n=93) | 0 |
| Mild at Week 36 (n=90) | 3 |
| Moderate at Week 36 (n=90) | 0 |
| Severe at Week 36 (n=90) | 0 |
| Mild at Week 52/early termination (n=100) | 3 |
| Moderate at Week 52/early termination (n=100) | 0 |
| Severe at Week 52/early termination (n=100) | 1 |
| Mild at Week 53/early termination (n=78) | 2 |
| Moderate at Week 53/early termination (n=78) | 1 |
| Severe at Week 53/early termination (n=78) | 0 |
DVT was defined if a segment of the deep vein of the lower limb was not compressible or a previous compressive vein became non compressive or there was no flow in the underlying vessel. Symptoms of DVT included pain in the lower limb, localized tenderness, swelling, pitting edema, collateral superficial veins (non-varicose), and skin redness. The symptom was assessed as mild, moderate or severe.
| Participants | Pregabalin |
|---|---|
| Mild at Baseline (n=103) | 0 |
| Moderate at Baseline (n=103) | 0 |
| Severe at Baseline (n=103) | 0 |
| Mild at Week 4 (n=101) | 0 |
| Moderate at Week 4 (n=101) | 0 |
| Severe at Week 4 (n=101) | 0 |
| Mild at Week 20 (n=93) | 0 |
| Moderate at Week 20 (n=93) | 0 |
| Severe at Week 20 (n=93) | 0 |
| Mild at Week 36 (n=90) | 0 |
| Moderate at Week 36 (n=90) | 0 |
| Severe at Week 36 (n=90) | 0 |
| Mild at Week 52/early termination (n=100) | 0 |
| Moderate at Week 52/early termination (n=100) | 0 |
| Severe at Week 52/early termination (n=100) | 0 |
| Mild at Week 53/early termination (n=78) | 0 |
| Moderate at Week 53/early termination (n=78) | 0 |
| Severe at Week 53/early termination (n=78) | 0 |
DVT was defined if a segment of the deep vein of the lower limb was not compressible or a previous compressive vein became non compressive or there was no flow in the underlying vessel. Symptoms of DVT included pain in the lower limb, localized tenderness, swelling, pitting edema, collateral superficial veins (non-varicose), and skin redness. The symptom was assessed as mild, moderate or severe.
| Participants | Pregabalin |
|---|---|
| Mild at Baseline (n=103) | 4 |
| Moderate at Baseline (n=103) | 2 |
| Severe at Baseline (n=103) | 0 |
| Mild at Week 4 (n=101) | 3 |
| Moderate at Week 4 (n=101) | 2 |
| Severe at Week 4 (n=101) | 0 |
| Mild at Week 20 (n=93) | 3 |
| Moderate at Week 20 (n=93) | 2 |
| Severe at Week 20 (n=93) | 0 |
| Mild at Week 36 (n=90) | 4 |
| Moderate at Week 36 (n=90) | 1 |
| Severe at Week 36 (n=90) | 0 |
| Mild at Week 52/early termination (n=100) | 7 |
| Moderate at Week 52/early termination (n=100) | 0 |
| Severe at Week 52/early termination (n=100) | 0 |
| Mild at Week 53/early termination (n=78) | 5 |
| Moderate at Week 53/early termination (n=78) | 0 |
| Severe at Week 53/early termination (n=78) | 0 |
DVT was defined if a segment of the deep vein of the lower limb was not compressible or a previous compressive vein became non compressive or there was no flow in the underlying vessel. Symptoms of DVT included pain in the lower limb, localized tenderness, swelling, pitting edema, collateral superficial veins (non-varicose), and skin redness. The symptom was assessed as mild, moderate or severe.
| Participants | Pregabalin |
|---|---|
| Mild at Baseline (n=103) | 6 |
| Moderate at Baseline (n=103) | 1 |
| Severe at Baseline (n=103) | 0 |
| Mild at Week 4 (n=101) | 5 |
| Moderate at Week 4 (n=101) | 2 |
| Severe at Week 4 (n=101) | 0 |
| Mild at Week 20 (n=93) | 4 |
| Moderate at Week 20 (n=93) | 1 |
| Severe at Week 20 (n=93) | 0 |
| Mild at Week 36 (n=90) | 7 |
| Moderate at Week 36 (n=90) | 0 |
| Severe at Week 36 (n=90) | 0 |
| Mild at Week 52/early termination (n=100) | 8 |
| Moderate at Week 52/early termination (n=100) | 0 |
| Severe at Week 52/early termination (n=100) | 0 |
| Mild at Week 53/early termination (n=78) | 4 |
| Moderate at Week 53/early termination (n=78) | 0 |
| Severe at Week 53/early termination (n=78) | 0 |
DVT was defined if a segment of the deep vein of the lower limb was not compressible or a previous compressive vein became non compressive or there was no flow in the underlying vessel. Symptoms of DVT included pain in the lower limb, localized tenderness, swelling, pitting edema, collateral superficial veins (non-varicose), and skin redness. The symptom was assessed as mild, moderate or severe.
| Participants | Pregabalin |
|---|---|
| Mild at Baseline (n=103) | 0 |
| Moderate at Baseline (n=103) | 0 |
| Severe at Baseline (n=103) | 0 |
| Mild at Week 4 (n=101) | 0 |
| Moderate at Week 4 (n=101) | 0 |
| Severe at Week 4 (n=101) | 0 |
| Mild at Week 20 (n=93) | 0 |
| Moderate at Week 20 (n=93) | 0 |
| Severe at Week 20 (n=93) | 0 |
| Mild at Week 36 (n=90) | 0 |
| Moderate at Week 36 (n=90) | 0 |
| Severe at Week 36 (n=90) | 0 |
| Mild at Week 52/early termination (n=100) | 0 |
| Moderate at Week 52/early termination (n=100) | 0 |
| Severe at Week 52/early termination (n=100) | 0 |
| Mild at Week 53/early termination (n=78) | 0 |
| Moderate at Week 53/early termination (n=78) | 0 |
| Severe at Week 53/early termination (n=78) | 0 |
DVT was defined if a segment of the deep vein of the lower limb was not compressible or a previous compressive vein became non compressive or there was no flow in the underlying vessel. Symptoms of DVT included pain in the lower limb, localized tenderness, swelling, pitting edema, collateral superficial veins (non-varicose), and skin redness. The symptom was assessed as mild, moderate or severe.
| Participants | Pregabalin |
|---|---|
| Mild at Baseline (n=103) | 0 |
| Moderate at Baseline (n=103) | 0 |
| Severe at Baseline (n=103) | 0 |
| Mild at Week 4 (n=101) | 0 |
| Moderate at Week 4 (n=101) | 0 |
| Severe at Week 4 (n=101) | 0 |
| Mild at Week 20 (n=93) | 1 |
| Moderate at Week 20 (n=93) | 0 |
| Severe at Week 20 (n=93) | 0 |
| Mild at Week 36 (n=90) | 0 |
| Moderate at Week 36 (n=90) | 0 |
| Severe at Week 36 (n=90) | 0 |
| Mild at Week 52/early termination (n=100) | 0 |
| Moderate at Week 52/early termination (n=100) | 0 |
| Severe at Week 52/early termination (n=100) | 0 |
| Mild at Week 53/early termination (n=78) | 0 |
| Moderate at Week 53/early termination (n=78) | 0 |
| Severe at Week 53/early termination (n=78) | 0 |
Number of participants who had normal visual field at baseline and showed abnormal result after the study treatment, assessed by confrontational visual field test (neurological examination).
| Participants | Pregabalin |
|---|---|
| Right eye | 0 |
| Left eye | 0 |
Worsening of the condition relative to baseline was reported as deteriorated. Assessment categories are as follows: normal or abnormal for Cranial Nerve Function, Mental State, and Coordination; normal, mild, moderate, or severe ataxia for Gait; none/absent, normal, or hyper-reflexic for Deep Tendon Reflexes; absent or present for Abnormal Reflexes; normal, mild, moderate, or severe weakness for Muscle Strength; slight, more marked, or considerable increase, or affected parts rigid in flexion or extension for Muscle Tone; absent or present for Sensory Function.
| Participants | Pregabalin |
|---|---|
| Cranial Nerve Function | 0 |
| Mental State | 0 |
| Coordination: Right (R)- Finger to Nose | 0 |
| Coordination: Left (L)- Finger to Nose | 2 |
| Coordination: R- Finger Tapping | 1 |
| Coordination: L- Finger Tapping | 0 |
| Coordination: R- Rapid Alternating Hand Movement | 1 |
| Coordination: L- Rapid Alternating Hand Movement | 2 |
| Coordination: Romberg Test | 1 |
| Gait | 1 |
| Deep Tendon Reflexes: R- Brachioradialis | 1 |
| Deep Tendon Reflexes: L- Brachioradialis | 1 |
| Deep Tendon Reflexes: R-Patellar | 3 |
| Deep Tendon Reflexes: L-Patellar | 3 |
| Deep Tendon Reflexes: R- Achilles | 2 |
| Deep Tendon Reflexes: L- Achilles | 3 |
| Abnormal Reflexes | 1 |
| Muscle Strength: R- Upper Limb | 1 |
| Muscle Strength: L- Upper Limb | 2 |
| Muscle Strength: R- Lower Limb | 1 |
| Muscle Strength: L- Lower Limb | 2 |
| Muscle Tone: R- Upper Limb | 1 |
| Muscle Tone: L- Upper Limb | 1 |
| Muscle Tone: R- Lower Limb | 5 |
| Muscle Tone: L- Lower Limb | 5 |
| Sensory Function: Anesthesia | 0 |
| Sensory Function: Hypesthesia | 1 |
| Sensory Function: Allodynia | 1 |
| Sensory Function: Hyperalgesia | 2 |
The Sheehan-STS is an 8-item prospective rating scale that tracks treatment-emergent suicidal ideation and behaviors. Participants who reported a score of ≥1 (5-point scale ranging from 0: not at all to 4: extremely) for Item 2, 3, 4 or 5 of the Sheehan-STS prognostic scale is considered to have suicidal ideation as the scores are mapped to Category 4 (suicide ideation) of the Columbia Classification Algorithm of Suicide Assessment.
| Participants | Pregabalin |
|---|---|
| Baseline (n=103) | 3 |
| Week 2 (n=102) | 2 |
| Week 4 (n=101) | 1 |
| Week 8 (n=99) | 0 |
| Week 12 (n=96) | 0 |
| Week 20 (n=93) | 2 |
| Week 28 (n=91) | 2 |
| Week 36 (n=90) | 2 |
| Week 44 (n=85) | 2 |
| Week 52 (n=101) | 0 |
The main component of the SF-MPQ consists of 15 descriptors (11 sensory; 4 affective) which are rated on an intensity scale as 0 = none, 1 = mild, 2 = moderate or 3 = severe. Range: 0 to 45 for total score. Change = observation mean minus baseline mean. Negative change indicated improvement.
| Score on a scale | Pregabalin |
|---|---|
| Week 2 (n=103) | -4.2 (-5.4 to -3.0) |
| Week 4 (n=102) | -5.2 (-6.4 to -4.0) |
| Week 8 (n=99) | -5.3 (-6.6 to -4.0) |
| Week 12 (n=98) | -5.7 (-7.3 to -4.2) |
| Week 20 (n=95) | -6.1 (-7.6 to -4.7) |
| Week 28 (n=92) | -5.1 (-6.6 to -3.6) |
| Week 36 (n=91) | -5.0 (-6.5 to -3.5) |
| Week 44 (n=87) | -4.4 (-6.1 to -2.8) |
| Week 52 (n=85) | -5.0 (-6.6 to -3.4) |
| Week 52 (LOCF, n=103) | -4.6 (-6.2 to -3.0) |
The main component of the SF-MPQ consists of 15 descriptors (11 sensory; 4 affective) which are rated on an intensity scale as 0 = none, 1 = mild, 2 = moderate or 3 = severe. Range: 0 to 33 for sensory score. Change = observation mean minus baseline mean. Negative change indicated improvement.
| Score on a scale | Pregabalin |
|---|---|
| Week 2 (n=103) | -3.1 (-4.1 to -2.2) |
| Week 4 (n=102) | -3.9 (-4.8 to -3.0) |
| Week 8 (n=99) | -3.9 (-4.9 to -3.0) |
| Week 12 (n=98) | -4.2 (-5.4 to -3.1) |
| Week 20 (n=95) | -4.5 (-5.6 to -3.4) |
| Week 28 (n=92) | -3.8 (-5.0 to -2.7) |
| Week 36 (n=91) | -3.7 (-4.8 to -2.6) |
| Week 44 (n=87) | -3.1 (-4.4 to -1.9) |
| Week 52 (n=85) | -3.6 (-4.8 to -2.4) |
| Week 52 (LOCF, n=103) | -3.6 (-4.8 to -2.4) |
The main component of the SF-MPQ consists of 15 descriptors (11 sensory; 4 affective) which are rated on an intensity scale as 0 = none, 1 = mild, 2 = moderate or 3 = severe. Range: 0 to 12 for affective score. Change = observation mean minus baseline mean. Negative change indicated improvement.
| Score on a scale | Pregabalin |
|---|---|
| Week 2 (n=103) | -1.1 (-1.5 to -0.5) |
| Week 4 (n=102) | -1.3 (-1.7 to -0.8) |
| Week 8 (n=99) | -1.3 (-1.8 to -0.9) |
| Week 12 (n=98) | -1.5 (-2.0 to -1.0) |
| Week 20 (n=95) | -1.6 (-2.1 to -1.2) |
| Week 28 (n=92) | -1.3 (-1.8 to -0.9) |
| Week 36 (n=91) | -1.3 (-1.8 to -0.7) |
| Week 44 (n=87) | -1.3 (-1.9 to -0.7) |
| Week 52 (n=85) | -1.4 (-1.9 to -0.9) |
| Week 52 (LOCF, n=103) | -1.0 (-1.5 to -0.5) |
The mBPI-10 is a self administered questionnaire that assesses pain interference with functional activities over the past week. These items are measured on an 11 point scale, ranging from "does not interfere" (0) to "completely interferes" (10). A composite score, the Pain Interference Index, will be calculated by averaging the 10 items that comprise the scale. Change = observation mean at Week 52 minus baseline mean.
| Score on a scale | Pregabalin |
|---|---|
| Change From Baseline in the Modified Brief Pain Inventory (10 Item) (mBPI-10)Total Scores at Last Evaluation Score | -1.4 (-1.9 to -0.9) |
Collected over 53 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pregabalin | — | 19/103 (18.4%) | 91/103 (88.3%) |
| Event | Pregabalin |
|---|---|
| CellulitisInfections and infestations | 2/103 |
| Cerebral infarctionNervous system disorders | 2/103 |
| Arteriosclerosis coronary arteryCardiac disorders | 1/103 |
| Anal fistulaGastrointestinal disorders | 1/103 |
| Colonic polypGastrointestinal disorders | 1/103 |
| Inguinal herniaGastrointestinal disorders | 1/103 |
| MelaenaGastrointestinal disorders | 1/103 |
| Tooth development disorderGastrointestinal disorders | 1/103 |
| Cholangitis acuteHepatobiliary disorders | 1/103 |
| Infected skin ulcerInfections and infestations | 1/103 |
| Event | Pregabalin |
|---|---|
| SomnolenceNervous system disorders | 53/103 |
| Weight increasedInvestigations | 31/103 |
| NasopharyngitisInfections and infestations | 26/103 |
| DizzinessNervous system disorders | 24/103 |
| Oedema peripheralGeneral disorders | 18/103 |
| FallInjury, poisoning and procedural complications | 13/103 |
| ConstipationGastrointestinal disorders | 8/103 |
| ContusionInjury, poisoning and procedural complications | 8/103 |
| Back painMusculoskeletal and connective tissue disorders | 8/103 |
| RashSkin and subcutaneous tissue disorders | 8/103 |
| Age, Customized(Participants) | Pregabalin |
|---|---|
| >=18 and <45 years | 15 |
| >= 45 and <65 years | 60 |
| >=65 years | 28 |
| Sex: Female, Male(Participants) | Pregabalin |
|---|---|
| Female | 22 |
| Male | 81 |
The record gives a start of Sep 2010, a primary completion of Mar 2012 and a completion of Mar 2012. It does not say whether these dates are actual or estimated.
Results were first posted in May 2013, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pregabalin
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. →